ultimate-guide
Ketamine for Treatment-Resistant Depression: A Patient Guide
Table of Contents
- What Is Treatment-Resistant Depression and When Is Ketamine Considered?
- How Ketamine Works for Treatment-Resistant Depression
- Esketamine Nasal Spray vs. IV Ketamine Infusion
- Ketamine Therapy Eligibility Criteria: Who Qualifies?
- What to Expect During a Ketamine Infusion Session
- Ketamine Infusion Therapy Side Effects and Safety
- How Long Does Ketamine Treatment Last?
- Conclusion: Making Your Decision
- Frequently Asked Questions
Last Updated: September 9, 2026
When standard antidepressants fail to relieve major depressive disorder, many patients feel they have run out of options. Ketamine for treatment-resistant depression has emerged as a rapid-acting alternative that works through a different mechanism than traditional pharmacotherapy, offering relief in hours rather than weeks. This guide from Medical Aesthetics and Lasers explains how this therapy works, who qualifies, and what the treatment experience actually involves so you can make an informed decision alongside your psychiatric care team.
Treatment-resistant depression is generally defined as major depressive disorder that does not respond adequately to two or more antidepressant trials at adequate doses and duration. For these patients, ketamine represents a fundamentally different approach: instead of targeting serotonin or norepinephrine, it modulates the glutamate system, specifically acting as an NMDA receptor antagonist. Below, we'll walk through the science, the two main delivery methods, and the practical logistics of treatment.
What Is Treatment-Resistant Depression and When Is Ketamine Considered?
Treatment-resistant depression is a diagnosis of exclusion reached after multiple standard treatments have failed. Most psychiatrists consider a patient treatment-resistant when they have not achieved clinical remission after two or more adequate trials of different antidepressant classes, often combined with psychotherapy.
Ketamine is typically considered when other options have been exhausted, including switching antidepressants, augmenting with mood stabilizers or atypical antipsychotics, and evidence-based psychotherapy. Many patients also try electroconvulsive therapy or transcranial magnetic stimulation before exploring ketamine.
The key distinction is that ketamine is not a first-line treatment. It is reserved for severe, persistent depression, often accompanied by suicidal ideation, where the speed of antidepressant response matters. Because intravenous infusion and esketamine nasal spray can produce effects within hours, they are frequently used in acute clinical settings where waiting weeks for a standard drug to work is not acceptable.
How Ketamine Works for Treatment-Resistant Depression
The mechanism of action for ketamine in treatment-resistant depression represents a fundamental shift from conventional antidepressants. Traditional SSRIs and SNRIs work by increasing the availability of monoamine neurotransmitters like serotonin and norepinephrine at the synaptic cleft, a process that takes weeks to produce downstream receptor changes. Ketamine, by contrast, works on the glutamate system, the primary excitatory neurotransmitter in the brain, and produces effects within hours.
At the molecular level, ketamine acts as a non-competitive antagonist at the NMDA receptor. This blockade leads to a rapid increase in the release of brain-derived neurotrophic factor (BDNF), a protein critical for neuronal survival, growth, and synaptic plasticity. The surge in BDNF activates the mTOR signaling pathway, which stimulates the formation of new dendritic spines and synapses within hours of a single infusion. This process, known as synaptogenesis, is believed to be the core mechanism that reverses the synaptic atrophy and neuronal loss observed in the prefrontal cortex and hippocampus of patients with chronic, severe depression.
This neuroplasticity-based mechanism explains the key clinical differences from standard antidepressants. While conventional drugs rely on slow, gradual modulation of receptor sensitivity, ketamine directly promotes rapid structural remodeling of neural circuits. This is why a single infusion can produce a significant antidepressant response within 2 to 4 hours, with peak effects often observed at 24 hours. For patients with treatment-resistant depression, this speed is not just a convenience, it can be life-saving, particularly when suicidal ideation is present.
Research suggests that a metabolite called hydroxynorketamine (HNK) may contribute to the antidepressant effect. While the exact contribution of HNK versus the parent ketamine compound is still under investigation, this area of study highlights that the drug's action is more complex than simple NMDA receptor blockade.
For patients, the practical implication is that ketamine does not 'fix' a chemical imbalance in the same way a daily SSRI might. Instead, it creates a temporary window of heightened neuroplasticity, a period where the brain is more amenable to forming new, healthier neural connections. This is why the treatment is rarely a one-time event; it is a course of therapy designed to capitalize on this plasticity window.
Esketamine Nasal Spray vs. IV Ketamine Infusion
Patients have two primary options for ketamine for treatment-resistant depression: FDA-approved esketamine nasal spray or intravenous infusion of racemic ketamine, which is used off-label. The choice depends on availability, cost, and clinical context.
Esketamine, marketed under the brand name Spravato, received FDA approval specifically for treatment-resistant depression. It must be administered in a certified medical office where blood pressure monitoring is available, and patients are observed for at least two hours after dosing. The nasal spray is covered by many insurance plans when prior authorization is obtained, though it requires ongoing psychiatric evaluation.
IV ketamine infusion uses racemic ketamine, a mixture of two molecular forms, delivered over roughly 40 minutes. It has a longer track record in clinical practice and offers more flexible dosing. Because it is off-label, insurance coverage is less predictable, and patients typically pay out of pocket. Many clinics, including physician-supervised practices, offer IV infusion because it allows precise titration and immediate medical response if adverse events occur.
| Option | FDA Status | Administration | Typical Setting | Insurance |
|---|---|---|---|---|
| Esketamine nasal spray | FDA-approved | Self-administered spray under supervision | Certified clinic | Often covered with prior authorization |
| IV ketamine infusion | Off-label | Intravenous infusion by medical staff | Physician-supervised clinic | Variable, often out-of-pocket |
Ketamine Therapy Eligibility Criteria: Who Qualifies?
Ketamine therapy eligibility criteria begin with a thorough psychiatric evaluation to confirm the diagnosis of treatment-resistant depression and rule out contraindications. This evaluation typically includes a review of past treatment trials, current medications, and a structured assessment of mood and suicidal ideation.
Not everyone is a candidate. Ketamine is generally avoided in patients with uncontrolled hypertension, certain cardiovascular conditions, active substance use disorders, or a history of psychosis. Because ketamine can cause transient increases in blood pressure, patient monitoring during infusion is standard of care. Pregnant women and those with severe liver disease are typically excluded.
A common misconception is that ketamine therapy is experimental. While IV infusion is off-label, it has been used in clinical practice for years, and the FDA-approved esketamine nasal spray validates the mechanism for treatment-resistant depression. Suitability is always determined after medical evaluation.
What to Expect During a Ketamine Infusion Session
An IV ketamine infusion session typically lasts between 40 minutes and two hours, depending on the therapeutic protocol. You will be seated in a comfortable recliner in a quiet room, and a physician or nurse will place an IV line. Throughout the infusion, your blood pressure and heart rate are monitored continuously.
During the infusion, many patients experience a dissociative state. This can feel like floating, altered perception of time, or a sense of detachment from the body. These dissociative side effects are temporary and typically resolve within an hour after the infusion ends. Some patients find the experience calming; others find it unusual but tolerable. Having a support person drive you home afterward is required.
The number of sessions varies. Many therapeutic protocols begin with a treatment cycle of two to three infusions per week for the first few weeks, then taper to maintenance. Each clinic designs its protocol based on the patient's response and the severity of symptoms.
Ketamine Infusion Therapy Side Effects and Safety
Ketamine infusion therapy side effects are generally transient and manageable when treatment is physician-supervised. The most common effects include dizziness, nausea, headache, and a temporary increase in blood pressure. Dissociative symptoms are expected during the infusion but resolve quickly.
Serious adverse events are rare when patients are properly screened. The most significant risks involve cardiovascular changes, which is why blood pressure monitoring is non-negotiable. Patients with poorly controlled hypertension or heart disease are typically excluded from treatment. There is also a theoretical concern about bladder toxicity with long-term, high-frequency use, which is why maintenance schedules are carefully designed.
The distinction between esketamine and racemic ketamine matters for side effect profiles. Esketamine is generally better tolerated in terms of dissociative effects at equivalent doses, but both require medical observation.
How Long Does Ketamine Treatment Last?
The question of how long ketamine treatment lasts has two distinct answers: the duration of a single session's effects and the trajectory of the overall treatment plan. Understanding both is critical for setting realistic expectations and building a sustainable long-term strategy.
Duration of a Single Infusion's Effect
Clinical data from leading research groups show that a single IV ketamine infusion produces a significant antidepressant response that typically peaks within 24 hours. However, the durability of that single-dose response is highly variable. For many patients, the relief lasts for approximately 3 to 7 days. In a smaller subset of patients, a single infusion can provide relief for up to two weeks, but this is not the norm. This variability is why the initial treatment phase is structured as a series of infusions rather than a one-time event.
The Acute Treatment Phase
The standard acute-phase protocol involves a series of six infusions delivered over two to three weeks. A common schedule is two to three infusions per week. The goal of this induction phase is to achieve and sustain remission. Data indicate that a significant majority of patients who respond to ketamine do so within the first two weeks of this initial series. However, the response is not always linear; some patients may feel worse on a given day before improving after the next infusion. It is crucial to complete the full induction series before judging whether the treatment is effective.
The Maintenance Phase and 'Booster' Sessions
Once remission is achieved, the focus shifts to relapse prevention. The effects of ketamine are not permanent, and without a maintenance plan, most patients will relapse within a few weeks to a month. This is where the concept of 'booster' sessions becomes central. A common pattern in clinical practice is for patients to return for a single maintenance infusion every 2 to 4 weeks. The exact interval is determined by the individual's response and the duration of their symptom relief.
A practical strategy used by many clinics is to have the patient track their mood daily after the induction phase. When they notice a consistent return of depressive symptoms for two to three days, they schedule their next booster. This 'symptom-triggered' approach often allows patients to extend the interval between infusions over time. Some patients find they can stretch the interval to 6 to 8 weeks, while others may require a fixed schedule to maintain stability.
Long-Term Relapse Prevention: The Missing Link
Most clinical guides stop at the booster schedule, but the most successful long-term outcomes involve a more holistic strategy. Ketamine provides a window of relief and neuroplasticity, but it does not automatically teach the brain new, healthier thought patterns. The most durable results are seen in patients who use this window to engage in other therapeutic work.
A common pattern among patients who successfully sustain remission is the integration of structured psychotherapy, such as cognitive behavioral therapy (CBT) or dialectical behavior therapy (DBT), alongside their maintenance infusions. The period of relief from ketamine is an ideal time to do the difficult work of challenging negative thought patterns and building new coping skills, as the brain is more adaptable during this time.
Additionally, lifestyle factors play a significant role in extending the interval between boosters. Patients who maintain a consistent sleep schedule, engage in regular aerobic exercise, and practice stress-reduction techniques like mindfulness often report that their maintenance intervals can be extended. These practices support the same neuroplasticity pathways that ketamine activates, creating a synergistic effect. The goal is not to be on ketamine indefinitely, but to use it as a tool to build a more resilient brain that can eventually maintain stability with less frequent pharmacological support.
Conclusion: Making Your Decision
Ketamine for treatment-resistant depression offers genuine hope for patients who have not found relief through conventional means, but it requires commitment to a structured treatment plan and realistic expectations about maintenance. The decision to pursue this therapy should be made collaboratively with your psychiatrist and a physician-supervised clinic that conducts thorough eligibility screening.
At Medical Aesthetics and Lasers, physician-supervised ketamine therapy is offered for certain treatment-resistant psychiatric conditions, including severe depression, when medically appropriate. Led by Dr. Ayaz Khan, MD, the practice evaluates each patient individually to determine suitability, with a focus on safety and compassionate care. If you have exhausted other options and want to explore whether ketamine therapy is right for you, request a consultation at medicalaestheticsandlasers.com or call 570-323-3106 to discuss your history with a qualified physician.
Frequently Asked Questions
How does ketamine work for treatment-resistant depression?
Unlike traditional antidepressants that target serotonin or norepinephrine, ketamine blocks the NMDA receptor for glutamate. This action triggers a rapid release of glutamate, which stimulates pathways that promote neuroplasticity and synaptogenesis. In practical terms, this means the brain can form new neural connections, often relieving depressive symptoms within hours or days rather than weeks. This rapid-acting antidepressant response is why ketamine is considered when standard pharmacotherapy has failed.
Is ketamine FDA-approved for depression?
Ketamine itself is not FDA-approved as a depression treatment. However, esketamine, a closely related compound delivered as a nasal spray, is FDA-approved for treatment-resistant depression when used alongside an oral antidepressant. Standard IV ketamine for depression is considered an off-label use but is a widely practiced therapeutic protocol. Your physician should explain whether you are receiving FDA-approved esketamine or off-label ketamine, and why one may be recommended over the other.
What are the common side effects of ketamine infusion therapy?
The most common ketamine infusion therapy side effects are temporary and include dissociative feelings, dizziness, nausea, and changes in blood pressure. Because of this, blood pressure monitoring is standard during and after each session. These effects typically resolve within an hour or two after the infusion ends. Your doctor will review your full medical history to screen for conditions that could increase risk, and you will be observed in the clinic until immediate effects subside.
How long do the effects of ketamine treatment last?
The acute effects of a single infusion last about 45 minutes to an hour, but the antidepressant response can last days to several weeks. Ketamine treatments are typically delivered as a series over a few weeks to build and sustain the response. After this initial treatment cycle, many patients move to a maintenance therapy schedule with infusions spaced weeks or months apart to prevent relapse. Your physician will tailor a schedule based on your individual response.
Who is a candidate for ketamine therapy?
Ketamine therapy eligibility criteria typically include a diagnosis of major depressive disorder that has not improved after trying at least two different antidepressants at adequate doses. Candidates undergo a thorough psychiatric evaluation to confirm the diagnosis and rule out conditions like bipolar disorder or psychosis, where ketamine may be inappropriate. A physical health screening is also required to check for uncontrolled high blood pressure, certain heart conditions, or a history of substance abuse, which could disqualify a patient.